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ABSTRACT 
The present work reports on the synthesis, anti-Trypanosoma cruzi activities and docking 
studies of a novel series of 2-(pyridin-2-yl)-1,3-thiazoles derived from 2-pyridine 
thiosemicarbazone. The majority of these compounds are potent cruzain inhibitors and 
showed excellent inhibition on the trypomastigote form of the parasite, and the resulting 
structure-activity relationships are discussed. Together, these data present a novel series of 
thiazolylhydrazones with potential effects against Chagas disease and they could be 
important leads in continuing development against Chagas disease. 
 
Key words: Chagas disease; T. cruzi; thiazoles; hydrazones; 2-pyridine thiosemicarbazone. 
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1. INTRODUCTION 
Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening 
illness caused by the protozoan parasite Trypanosoma cruzi (T. cruzi)[1]. About 7-8 million 
people worldwide are estimated to be infected with T. cruzi, mainly in Latin America.  
Over the years, numerous chemical classes against T. cruzi have become available, but 
there is still no effective treatment for all phases of the disease[2]. Recent research has 
pointed to the ergosterol biosynthetic pathway as a biochemical target[3,4]. Azole 
derivatives such as posaconazole and ravuconazole, have been tested and presented 
trypanocidal activity, but they are not yet available as therapeutics[5–7]. 
Despite the efforts of many investigators in the research of a new anti-Chagas drugs, only 
two drugs are currently used to treat it, nifurtimox and benznidazole[6,8] (Figure 1). 
Current chemotherapy for Chagas disease is unsatisfactory due to its limited efficacy, 
particularly in the chronic phase, with frequent side effects that can lead to discontinuation 
of treatment. 
 
PLEASE INSERT FIGURE 1 HERE 
 
Among a number of drug targets being investigated for Chagas disease, cruzain, the major 
cysteine protease active in the parasite, is a prominent candidate[9–12]. Cruzain is a 
cathepsin-L-like protease of the papain family thought to be important for intracellular 
replication and differentiation of the T. cruzi parasite[13]. Among the chemical groups 
explored for anti-Chagas activity, thiazolylhydrazones are noteworthy because of their wide 
biological, especially anti-parasitic, activities[14–17].  
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In 2004, Greenbaum et al. observed that thiosemicarbazones with a pyridyl moiety inhibit 
cruzain catalytic activity[18]. Subsequent studies have demonstrated the trypanocidal 
activity of thiosemicarbazones and their metal complexes. Recently, Caputo et al. have 
demonstrated trypanocidal activity for a series of 4-arylthiazolylhydrazones[19], with a 
broad and potent activity for all forms of the parasite. Recently studies have reported 
inhibition of the cysteine protease cruzain by thiosemicarbazones[16]. Our efforts toward 
new antichagasic drug since 2010 have led us to a variety of thiosemicarbazones and 
thiazolyl hydrazones as trypanocidal agents [16,19–22]. The promising results achieved by 
compounds bearing a thiazole ring motivated us to investigate the trypanocidal activity of 
novel thiazolyl hydrazones derived from 2-pyridyl thiosemicarbazone, with changes being 
made in the phenyl ring attached in N2. In continuation of our search for bioactive 
molecules, we envisaged that the derivatization of the thiosemicarbazone group into 
thiazole moiety would generate novel templates, which are likely to exhibit anti-T. cruzi 
activity. We also investigate pyridines as trypanocidal agents because their wide 
applicability in organic synthesis, low price and facility in synthesis. Here, these 
compounds were tested in vitro against T. cruzi parasite epimastigote and trypomastigote 
forms, and cruzain protease. In this synthetic design of a structure-activity relationship 
(SAR) library, attention was paid to further explore substituents around the phenyl ring 
attached in thiazole ring (C9). This study generated basic SARs about tripomastigote form 
and cruzain enzyme around substituents in phenyl ring, and using the scaffold shown in 
Scheme 1. Specifically, we report the preparation of twenty-four 2-(pyridin-2-yl)-1,3-
thiazoles (3-27) by ultrasound-assisted synthesis. The synthesized compounds were 
characterized by IR, NMR and mass spectral studies. The 2-(pyridin-2-yl)-1,3-thiazoles 
were assayed for their in vitro anti-T. cruzi activity against the epimastigote and 
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trypomastigote forms of the parasite. Their cytotoxicity in mammalian cell cultures was 
also investigated. Further investigations on the possible involvement of 2-(pyridin-2-yl)-
1,3-thiazoles with cruzain activity as potential therapeutic targets were performed. 
2. RESULTS AND DISCUSSION 
2.1. Chemistry 
2-(pyridin-2-yl)thiosemicarbazones (2a-b) were prepared by reacting commercially 
available thiosemicarbazides with the appropriate aldehyde or ketone (1:1.2 mol ratio) via 
Schiff base condensations using ultrasound irradiation in presence of a catalytic amount of 
AcOH. This reaction condition led to high yields (80-90%). 2-(pyridin-2-yl)-1,3-thiazoles 
(3-26) were prepared via Hantsch cyclization between 2-(pyridin-2-yl)thiosemicarbazones 
(2a-b) and substituted 2-bromoacetophenones (Scheme 1). These reactions proceed well 
upon refluxing with ethanol (2-4 h), but here we adapted this to ultrasound conditions at 
room temperature[23] using 2-propanol as solvent[24]. This resulted in good yields (50-
85%) and shorter reaction times (60 min in most cases) compared with the reflux protocol. 
 
PLEASE INSERT SCHEME 1 HERE 
 
Microanalysis and NMR data are compatible with the proposed compounds. In theory, two 
geometrical isomers (E and Z) about the imine (C=N) double bond are possible for the 
thiosemicarbazones. However, analysis of the 1H NMR spectra of the target compound 
indicated one predominant isomer; the E isomer by comparison with known analogues[25]. 
Intramolecular H-bonding involving the proton attached to N4 (in DMSO) with the imine 
N-atom leads to a distinctive singlet around 10.2 ppm[25] and this is also seen here. 
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Once thiosemicarbazones were characterized, the respective 2-(pyridin-2-yl)-1,3-thiazoles 
were characterized by usual spectroscopy. As exemplified with the 1H NMR analysis of (2-
(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-phenyl-1,3-thiazole (15), the singlet peak at δ 2.43 
corresponds to the methyl group. The aromatic protons occurred as doublets or triplets. For 
the pyridyl ring, peaks were observed at δ 7.76, 8.23, 8.35 and 8.73. For the aromatic ring 
coupled to the thiazole ring, doublet and triplet peaks were found at δ 7.30, 7.39 and 7.85. 
For the thiazole ring, a singlet at δ 7.44 was found. In addition, the NH proton appeared as 
broad singlet at δ 5.53. The 13C NMR spectrum of (15) the 13C=S resonance from the parent 
thiosemicarbazone disappeared while a new 13C-H resonance at ~ 106 ppm appeared, 
confirming cyclization in addition to the resonance at ~169 ppm. Quaternary carbon peaks 
were confirmed by DEPT experiments to appear at δ 134.2, 140.1, 150.0 and 168.9. Peaks 
of the pyridine aromatic carbons were found at δ 123.6, 125.6, 143.9, 147.5, and 150.0. 
Resonances from the phenyl ring coupled to the thiazole ring were observed at δ 126.0, 
128.4, 129.2 and 134.2. A combination of elemental analysis (C, H, N), UV, IR and HRMS 
confirmed the purity and identity of all the compounds. 
 
PLEASE INSERT FIGURE 2 HERE 
 
2.2. X-Ray crystallography 
The X-ray crystal structure of 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-
1,3-thiazole (4) is shown in Figure 2. Crystal and refinement data are summarized in Table 
1. The dihedral angles C(11)-C(10)-C(9)-N(4), C(9)-N(4)-C(7)-N(3), C(7)-N(3)-N(2)-C(6), 
N(2)-C(6)-C(5)-C(4) and C(16)-C(13)-C(12)-C(11) of -177.84°, -179.48°, -176.60°, -
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176.54° and 178.43° respectively indicate that the molecule is close to planar. In the 
thiazole ring, two significantly different C-N bonds are found viz. C9-N4 (1.373(4) Å) and 
C7=N4 (1.265(5) Å) and C8=C9 is clearly a double bond (1.348(5) Å). It is apparent that 
compound (4) crystallises in the Z-isomeric form where intramolecular H-bonding with the 
pyridyl ring and the proton attached to N2 is seen (see Figure 2). In this case, the E-isomer 
cannot be stabilised by H-bonding due to the loss of the proton from N4 of the parent 
thiosemicarbazone.  
 
PLEASE INSERT TABLE 1 HERE 
 
2.3. Structure-Activity Relationships (SAR)  
To investigate the importance of substituents on the phenyl ring for the antiparasitic activity 
against trypomastigote form, compound (3) (without substituents) was compared with 
seven para substituted analogues. It was found that compounds (5), (6), (8) and (9) showed 
better anti-T. cruzi activity than (3), while compounds (4), (7) and (13) were less potent 
(see Table 2). For the chloro substituted compounds (9, 10 and 11), it was observed that the 
dichloro compounds (10 and 11) were equally trypanocidal, being 3-fold more potent than 
2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-chlorophenyl)-1,3-thiazole (9). The 
monobromo compounds (5) and (6) displayed activity intermediate of the mono and 
dichloro compounds. The presence of a methyl group attached to C8 (for compound 5) did 
not significantly affect biological activity. 
Comparing compound (14) with (3) (naphthyl and aryl, respectively), it was observed that 
the influence of a more bulky substituent increased the trypanocidal activity, probably 
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because of an increase in lipophilicity. For the nitro compounds (12) and (13), the position 
of the substituent affected trypanocidal activity. For compound (12), (meta substituted), a 
2-fold increase in activity was found relative to (13) (para substituted). 
Compounds (15) to (26) (derived from 2-acetyl pyridine) differed from compounds (3) to 
(14) (derived from 2-pyridine carbaldehyde) by a methyl group present in C6 (Scheme 1). 
Analysis of the activity of these compounds suggests a trend in which a methyl in C6 
increases the trypanocidal activity. Compounds (15) to (26) stand out, show high 
trypanocidal activity (trypomastigote form); with exception of (25), all compounds are 
more potent than reference drug benznidazole.  
The para substituted 2-(pyridin-2-yl)-1,3-thiazoles (16, 17, 18, 19, 20, 21 and 25) were less 
active than unsubstituted (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-phenyl-1,3-thiazole 
(15), which was the most potent compound tested in this this work. No correlation was 
observed between the electron withdrawing properties of the substituent and trypanocidal 
activity.  
For the isomeric dichloro compounds (22) and (23), we observed little change in 
trypanocidal activity. For the nitro compounds (24 and 25), the compound meta substituted 
(24) was 9-fold more potent than para substituted (25), (3.9 µM vs. 36.7 µM respectively).  
 
PLEASE INSERT TABLE 2 HERE 
 
From Table 3, it can be seen that (2-(pyridin-2-yl)ethylene)-1,3-thiazoles (15-26) (with a 
methyl attached to C6), had increased the trypanocidal activity for both trypomastigote and 
epimastigote in comparison with (2-(pyridin-2-yl)methylene)-1,3-thiazoles (3-14).  
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PLEASE INSERT TABLE 3 HERE 
 
Comparing compounds with nitro substituents across the (3-14) and (15-26) series, the 
biggest difference was observed for compounds (13/25) (meta substituted), with 3.9 µM 
against 74.2 µM and (12/25), para substituted, with 36.7 µM against 152.9 µM. 
Among all of the compounds in this work, the most potent were (10), (11) and (15). It 
should be noted that among twenty-four compounds designed for anti-Chagas activity, 
twenty compounds (3, 5, 6, 8-11, 14, 15-24 and 26) displayed better trypanocidal activity 
than benznidazole. 
Analyzing the antiparasitic activity against epimastigote form, benznidazole, which is the 
reference drug, exhibited an IC50 of 6.6 µM. Once again, the majority of derivatives were 
very active. In this case, only compounds (6), (20) and (22) were several times less potent 
than benznidazole. In contrast, compounds (5), (12), (15), (16), (17), (18), (19) and (21) 
displayed a better activity profile than benznidazole-treated parasites. 
A recent work describing 2-imino-1,3-thiazoles[16] (derivatives 26-46), that share an 
aryloxypropylimine instead of a pyridine ring, displayed lower trypanocidal effects when 
compared to these that possess a 2-pyridyl moiety, pointing out the importance of the 2-
pyridyl moiety for the trypanocidal activity. Figure 3 summarizes the main SAR for anti T. 
cruzi activity (tripomastigote form).  
 
PLEASE INSERT FIGURE 3 HERE 
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2.4. Cruzain inhibition activity 
Table 4 shows the inhibition of the enzyme cruzain of T. cruzi (TCC). The experimental 
protocol described by Ferreira[26] was utilized in this assay. All compounds were tested at 
a concentration of 100 µM, except for cases limited by solubility, in which the screening 
was performed at either 50 or 75 µM (as noted on Table 4). Compounds which inhibited 
enzyme activity by at least 70% in the screening had their IC50 determined. 
 
PLEASE INSERT TABLE 4 HERE 
 
Some works describe that 2-imino-1,3-thiazoles are trypanocidal agents by altering the 
ergosterol biosynthesis instead of inhibiting the catalytic activity of cruzain[16,19]. In this 
work we show that cruzain is potently inhibited by several compounds.  
Among all compounds tested, the most actives were (20) and (26), showing the lowest IC50 
values (0.04 ± 0.03 µM and 0.01 µM, respectively). Due to the low potency of some 
compounds and the absence of IC50 values, in some cases we made a discussion based in 
percentual inhibition of cruzain. 
Comparing para substituted compounds; the most active were (20), (16), (19) and (5), 
showing percentage of inhibition near 90%. For the dichloro compounds (10-11), 2-(2-
(pyridin-2-ylmethylene)hydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole (10) did not show 
any inhibition of cruzain, in contrast to 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(3,4-
dichlorophenyl)-1,3-thiazole (11), which displayed weak inhibition. For the nitro 
compounds (12-13), the positional change of the nitro group from para to meta had a huge 
impact on potency against cruzain: while the 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(3-
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nitrophenyl)-1,3-thiazole (12) shows IC50 = 1.3 ± 0.7 µM, 2-(2-(pyridin-2-
ylmethylene)hydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole (13) does not considerably inhibit 
the enzyme at 100 µM.  
To investigate the relative activity of thiosemicarbazone versus thiazole in cruzain 
inhibition, compounds (2a) and (3) were compared. Neither of these compounds inhibits 
the enzyme at the concentrations evaluated, but (15), an analogue of (3) differing only by 
the addition of a methyl group at C6 was shown to be a moderately potent inhibitor IC50 = 
1.3 ± 0.7 µM. Extrapolating the analysis by comparison of compounds (3-14) to 
compounds (15-26), which show an analogous difference, we observe that in seven cases 
the addition of the methyl considerably improved cruzain inhibition, while only for two 
compound pairs (5 vs 17 and 12 vs 24) the opposite effect was observed. Together, these 
results indicate the high importance of the methyl group at C6.  
Within the series (15-26), seven compounds had their IC50 values determined, and in five 
cases the potency was better than 0.5 µM. Among the para substituted compounds, (16) 
and (19) had very similar potencies. On the other hand, modifying the methyl substituent 
(16) to methoxy (20) increased the potency by an order of magnitude.  
For chlorine substituted compounds (21, 22 and 23), the pattern of substitution had a big 
impact on potency. While the para substituted compound was inactive, disubstituted 
compounds were cruzain inhibitors, and the 3,4-diCl compound (23) was 12 fold more 
potent than the 2,4-diCl (22). Comparing the isomeric nitro-compounds (meta (24) and 
para (25) substituted), no significant cruzain inhibition was observed.  
2.5. Cytotoxicity activity 
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To determine the toxicity profile of the compounds, cytotoxicity assay adapted from 
Ballell et al.[27] were performed with HepG2 cells, a human liver cell line commonly used 
for in vitro testing of toxicity[28]. Cells were incubated with the compounds at 
concentration of 100 µM for 48 hours. It is worth mentioning that a compound that can kill 
parasites is necessary but not sufficient to represent a good drug lead unless it also 
demonstrates low or non-toxicity among other criteria. As can be observed in Table 2 and 
3, only compound (7) (a fluorine derivative) exhibited toxicity for HepG2 (18.20 µM). The 
most of compounds were less cytotoxic for HepG2 at concentrations up to 85.11 µM, 
demonstrating the low toxicity profile of the compounds assayed.  
2.6. Docking Studies  
In order to understand a probable mechanism of action, we investigated the interaction of 
these compounds with cruzain (PDB ID: 3IUT) by docking studies. The binding mode for 
the ligands was determined as the highest (most positive) score among the possible 
solutions for each ligand, generated according to the CHEMPLP Score Function[29]. 
Figure 4 shows the superposition of the best docking solutions for compounds that have 
IC50 values experimentally determined for cruzain (5, 12, 15, 16, 19, 20, 22, 23, 26) and the 
crystallographic structure of the “KB2”, a high-efficient cruzain inhibitor cocrystallized 
ligand[30]. To compare in silico versus in vitro cruzain data, IC50 values were first 
converted into pIC50 values (equals – log10IC50 for cruzain inhibition, in units of moles per 
litre). 
 
PLEASE INSERT FIGURE 4 HERE 
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Figure 5 shows the trend between the calculated docking scores and the experimental pIC50 
data, which indicates the compounds with the highest pIC50 being most active. There is a 
clear correlation between the docking score and pIC50 supporting the hypothesis that the 
most tightly binding thiazoles are also the most potent cruzain inhibitors (i.e., greater in 
vitro pIC50 values). 
 
PLEASE INSERT FIGURE 5 HERE 
 
To identify the molecular reasons for the two extremes of potency, the highest (26) (IC50 = 
0.01 nM) and lowest (5) (IC50 = 9.5 nM) in vitro results, we performed a detailed analysis 
of the intermolecular interactions with the cruzain target. The principle structural 
differences between these two molecules are as follows: (i) the presence of a 4-
bromophenyl ring linked to the thiazole ring in molecule (5), instead of a naphthalene 
group in molecule (26); (ii) a methyl group on C6 (adjacent to the pyridyl ring) for 
molecule (26), rather than hydrogen for molecule (5). 
The difference between the binding modes of these two molecules is show in detail in 
Figure 6 and Table 5. It appears that the large hydrophobic naphthalene group in molecule 
(26) provides a greater contact surface for interactions with hydrophobic residues LEU67, 
MET68, ALA138 and LEU160 in the S2 cruzain subsite, which is known to accommodate 
hydrophobic groups. Compared with the bromophenyl group in (5). The hydrogen bond 
with the residue ASP161 is slightly shorter for the molecule (26) (2.5 Å) than for molecule 
(5) (2.8 Å). There is also a weak hydrogen bond with the CYS25 residue (3.4 Å). These 
finding imbue greater stability to the complex formed with (26) than (5), with docking 
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scores of 66.09 and 55.29, respectively. These findings corroborate the in vitro binding 
assay with the cruzain enzyme. 
 
PLEASE INSERT FIGURE 6 HERE 
 
PLEASE INSERT TABLE 5 HERE 
 
3. CONCLUSION 
The current investigation has revealed novel structure–activity relationships regarding 
aromatic substitution at the phenyl moiety of 2-(pyridin-2-yl)-1,3-thiazoles for the design of 
new drugs for the treatment of Chagas disease. The novel analogues (3-26) exhibited 
improve trypanocidal activity than thiosemicarbazones (2a-b), while showing a similar 
potency to standard drug in use for treatment of Chagas disease, Benznidazole. 
Compounds (10) and (11) were the most potent thiazoles with IC50 values of 1.2 µM for 
each compound. In addition, all of the novel thiazoles showed similar or greater 
trypanocidal efficacy than Benznidazole, with compounds (10) and (11) exhibiting highest 
efficacies overall. 
Structure–activity analysis did not reveal a correlation between ligands with electron-
donating or electron-withdrawing substituents in terms of trypanocidal activity. However, 
the in silico docking studies corroborate with in vitro cruzain inhibition, showing that the 
molecules with more stable or positive docking scores (i.e., greater in silico affinity for 
cruzain) are also the most potent cruzain inhibitors (i.e., greater in vitro pIC50 values). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4. EXPERIMENTAL SECTION 
4.1. Equipment and Reagents 
All reagents were used as purchased from commercial sources (Sigma-Aldrich, Acros 
Organics, Vetec or Fluka). Progress of the reactions was followed by thin-layer 
chromatography (TLC) analysis (Merck, silica gel 60 F254 in aluminium foil). Purity of the 
target compounds was confirmed by combustion analysis (for C, H, N, S) performed by a 
Carlo-Erba instrument (model EA 1110). Melting points were determined on an Fisatom 
430D electrothermal capillary melting point apparatus and were uncorrected. NMR spectra 
were measured on either a Varian UnityPlus 400MHz (400 MHz for 1H and 100 MHz for 
13C) or a Bruker AMX-300 MHz (300 MHz for 1H and 75.5 MHz for 13C) instruments. 
DMSO-d6 and D2O were purchased from CIL or Sigma-Aldrich. Chemical shifts are 
reported in ppm and multiplicities are given as s (singlet), d (doublet), t (triplet), m 
(multiplet), dd (double doublet), and coupling constants (J) in hertz. Mass spectrometry 
experiments were performed on a LC-IT-TOF (Shimadzu). Unless otherwise specified, ESI 
was carried out in the positive ion mode. Typical conditions were: capillary voltage of 3 kV 
and cone voltage of 30 V, and peak scan between 50-1000 m/z. IR spectra were recorded 
with a Brucker model IFS66 FT-IR spectrophotometer using KBr pellets.  
4.2. Crystallography 
Crystallographic data were collected on an Oxford Diffraction Gemini S Ultra CCD 
diffractometer at 296 K using MoKα radiation (2θmax = 50°). Data reduction and empirical 
absorption corrections were carried out with the CrysAlis Pro program (Oxford Diffraction 
vers. 171.33.42). The structure was solved by direct methods with SHELXS86 and refined 
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with SHELXL97[31]. All non-H-atoms were refined anisotropically and H-atoms were 
constrained at their estimated positions using a riding model. The thermal ellipsoid diagram 
was generated with ORTEP3[32]. All crystallographic calculations were carried out within 
the WinGX graphical user interface[33]. Crystallographic data of compound (4) have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication 
CCDC 980106. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre (Cambridge, UK) via www.ccdc.cam.ac.uk). 
4.3. General modified procedure for the synthesis of known thiosemicarbazones (2a-b) 
To a solution of 2-pyridine carbaldehyde (0.75 g, 7 mmol) (or acetyl-2-pyridine (0.85 g, 7 
mmol)) in 2-propanol (10 mL) was added thiosemicarbazide (0.64 g, 7 mmol) and few 
drops of acetic acid. The reaction vessel was placed in an ultrasonic bath (40 MHz, 180V) 
and irradiated for 120 min, at r.t. The precipitate was filtered off, washed with hexane then 
dried in desiccator under vacuum. Additional amount of desired compound could be 
recovered from the filtrate after cooling.  
4.3.1. 2-(Pyridin-2-ylmethylene)hydrazinecarbothioamide (2a) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, yield: 91 %. m.p. (ºC): 
167. IR (KBr): (C=C), 1606 (C=N), (N-H) cm-1. 1H NMR (300 MHz, DMSO-d6), δ ppm: 
7.35 (t, J = 4.9 Hz, 1H, Ar), 7.81 (t, J = 7.7 Hz, 1H, Ar), 8.09 (s, 1H, CH), 8.16 (broad s, 
1H, NH2), 8.26 (d, J = 8.0 Hz, 1H, Ar), 8.35 (broad s, 1H, NH2), 8.55 (d, J = 4.9 Hz, 1H, 
Ar), 11.63 (s, 1H, NH). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 120.2 (C, Ar), 124.0 (C, 
Ar), 136.5 (C, Ar), 142.5 (C=N), 149.2 (C, Ar), 153.3 (C, Ar), 178.3 (C=S, Ar). Anal. 
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Calcd for C7H8N4S: C, 46.65; H, 4.47; N, 31.09; S, 17.79; found: C, 46.58; H, 4.50; N, 
31.12; S, 17.71. HR-MS (ESI): 181.6730 [M + H]+. 
4.3.2. 2-[1-(2-Pyridinyl)ethylidene]hydrazinecarbothioamide (2b) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 86%, m.p. (ºC): 
170. IR (KBr, cm-1): 1553 (C=C), 1612 (C=N), 3066 (N-H). 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.37 (s, 3H, CH3), 7.37 (t, J = 6.1 Hz, 1H, Ar), 7.77 (t, J = 7.8 Hz, 1H, Ar), 8.12 
(broad s, 1H, NH2), 8.37 (broad s, 1H, NH2), 8.41 (d, J = 8.1 Hz, 1H, Ar), 8.56 (d, J = 5.5 
Hz, 1H, Ar), 10.30 (s, 1H, NH). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 12.12 (CH3), 
120.9 (C, Ar), 123.9 (C, Ar), 136.5 (C, Ar), 148.1 (C=N), 154.6 (C, Ar), 179.1 (C=S); 
Anal. Calcd for C8H10N4S: C, 49.46; H, 5.19; N, 28.84; S, 16.51; found: C, 49.42; H, 5.21; 
N, 28.79; S, 16.56. HR-MS (ESI): 195.0682 [M + H]+.  
4.4. General procedure for the synthesis of (3-26). Example for compound (3) 
2-(Pyridin-2-ylmethylene)hydrazinecarbothioamide (2a) (0.5 g, 2.78 mmol) was dissolved 
in 2-propanol (10 mL) and then the appropriate 2-bromoacetophenone (see Scheme 1) 
(0.79 g, 3.05 mmol) and calcium carbonate (0.42 g, 3.05 mmol) were added to a glass tube. 
The tube was placed in an ultrasonic bath (40 MHz, 180V) and irradiated for 60 min, at r.t. 
Hexane was added and the mixture was cooled in a freezer overnight. The precipitate was 
filtered off and washed with hexane then dried in a desiccator under vacuum. Additional 
amount of the desired compound were obtained from the filtrate after cooling. Pure 
products were obtained after recrystallization using the solvent system detailed below for 
each compound.  
4.4.1. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-phenyl-1,3-thiazole (3) 
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Crystallization from toluene/hexane 7:3, afforded yellow crystals. Yield: 86%, m.p. (ºC): 
170. 1H - NMR (300 MHz, DMSO-d6), δ ppm: 4.47 (broad s,1H, NH), 7.31 (t, J = 7.2 Hz, 
1H, Ar), 7.38-7.52 (m, 4H, 3H of Ar and 1H for CH of thiazole), 7.41 (t, J = 7.3 Hz, 2H, 
Ar), 7.49 (d, J = 5.7 Hz, 2H, Ar), 7.86 (d, J = 7.4 Hz, 1H, Ar), 7.97 (t, J = 9.2 Hz, 1H, Ar), 
8.10 (s, 1H, CH), 8.62 (d, J = 4.6 Hz, 1H, Ar). 13C NMR (100 MHz, DMSO-d6), δ ppm: 
104.5 (S-CH), 120.0 (C, Ar), 124.0 (C, Ar), 125.5 (C, Ar), 127.6 (C, Ar), 128.7 (C, Ar), 
139.2 (C, Ar), 147.7 (C, Ar), 150.6 (C, Ar), 151.8 (C=N), 167.5 (S-C=N). IR (KBr, cm-1): 
1553 (C=C), 1612 (C=N), 3066 (N-H) cm-1. Anal. Calcd for C15H12N4S: C, 64.26; H, 4.31; 
N, 19.98; S, 11.44; Found: C, 64.22; H, 4.38; N, 20.02; S, 11.42. HR-MS (ESI): 281.0842 
[M + H]+.  
4.4.2. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole (4) 
Crystallization from toluene/hexane 7:3, afforded dark red crystals, Yield: 79 %, m.p. (ºC): 
197. IR (KBr, cm-1): 1554 (C=N), 1612 (C=N), 3154 (N-H) cm-1. 1H NMR (400 MHz, 
DMSO-d6), δ ppm: 2.32 (s, 3H, CH3), 7.21 (d, J = 7.9 Hz, 2H, Ar), 7.29 (s, 1H, CH of 
thiazole), 7.36 (t, 1H, J = 7.4 Hz, Ar), 7.50 (broad s, 1H, NH), 7.75 (d, J = 8.1 Hz, 2H, Ar), 
7.84 (d, J = 7.6 Hz, 1H, Ar), 7.86 (t, J = 7.6 Hz, 1H, Ar), 8.06 (s, 1H, CH), 8.57 (d, J = 4.9 
Hz, 1H, Ar). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 20.8 (CH3), 104.0 (S-CH), 119.1 (C, 
Ar), 123.6 (C, Ar), 125.5 (C, Ar), 125.7 (C, Ar), 129.2 (C, Ar), 131.9 (C, Ar), 136.7 (C, 
Ar), 141.4 (C, Ar), 149.5 (Ar), 153.2 (C=N), 167.7 (S-C=N); Anal. Calcd for C16H14N4S: 
C, 65.28; H, 4.79; N, 19.03; S, 10.89; found: C, 65.26; H, 4.82; N, 19.09; S, 10.84. HR-MS 
(ESI): 295.0991 [M + H]+.  
4.4.3. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-bromophenyl)-1,3-thiazole (5) 
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Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 74 %, m.p. (ºC): 
205. IR (KBr, cm-1): 1569 (C=N), 1574 (C=N), 3151 (N-H); 1H NMR (400 MHz, DMSO-
d6), δ ppm: 3.42 (s, 1H, NH), 7.29 (s, 1H, CH of thiazole), 7.36 (t, J = 6.6 Hz, 1H, Ar), 7.45 
(s, 1H, CH), 7.59 (d, J = 8.6 Hz, 2H, Ar), 7.74 (d, J = 8.1 Hz, 1H, Ar), 7.80 (d, J = 8.6 Hz, 
2H, Ar), 7.86 (t, J = 7.5 Hz, 1H, Ar), 8.06 (d, J = 7.1 Hz, 1H), 8.57 (d, J = 4.9 Hz, 1H).13C 
NMR (75.5 MHz, DMSO-d6), δ ppm: 105.6 (S-CH), 119.7 (C, Ar), 121.1 (C, Ar), 127.1 (C, 
Ar), 128.0 (C, Ar), 129.6 (C, Ar), 134.2 (C, Ar), 137.3 (C, Ar), 137.5 (C, Ar), 141.9 (C, 
Ar), 149.7 (C, Ar), 153.4 (C=N), 168.3 (S-C=N). Anal. Calcd for C15H11BrN4S: C, 50.15; 
H, 3.09; N, 15.60; S, 8.93; found: C, 50.11; H, 3.06; N, 15.65; S, 8.97. HRMS (ESI): 
358.9608 [M + H]+. 
4.4.4. 5-methyl-2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-bromophenyl)-1,3-thiazole (6) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 58%, m.p. (ºC): 
202. IR (KBr, cm-1): 1554 (C=N), 1609 (C=N), 3152 (N-H); 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.43 (s, 3H, CH3), 7.91 (s, 1H, CH), 7.41-7.60 (m, 4H, Ar), 8.03-8.58 (m, 4H, 
Ar), 13.05 (broad s,1H, NH);13C NMR (75.5 MHz, DMSO-d6), δ ppm: 12.3 (CH3), 118.7 
(S-CH), 119.6 (C, Ar), 120.3 (C, Ar), 123.8 (C, Ar), 129.8 (C, Ar), 131.3 (C, Ar), 134.1 (C, 
Ar), 138.0 (C, Ar), 139.6 (C, Ar), 148.4 (C=N), 167.0 (S-C=N). Anal. Calcd for 
C16H13BrN4S: C, 51.48; H, 3.51; N, 15.01; S, 8.59; found: C, 51.53; H, 3.54; N, 15.04; S, 
8.62. HRMS (ESI): 374.9846 [M + H]+. 
4.4.5. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole (7) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 78%, m.p. (ºC): 
228. IR (KBr, cm-1): 1552 (C=N), 1613 (C=N), 3029 (N-H); 1H NMR (400 MHz, DMSO-
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d6), δ ppm: 4.92 (broad s, 1H, NH), 7.25 (t, J = 8.8 Hz, 2H, Ar), 7.45 (s, 1H, CH of 
thiazole), 7.65 (t, J = 6.3 Hz, 1H, Ar), 7.90 (dd, J = 5.6, 8.8 Hz, 2H, Ar), 8.08 (d, J = 8.0 
Hz, 1H, Ar), 8.15 (s, 1H, CH), 8.21 (t, J = 7.5 Hz, 1H, Ar), 8.70 (d, J = 5.0 Hz, 1H, Ar). 13C 
NMR (75.5 MHz, DMSO-d6), δ ppm: 105.4 (S-CH), 115.4 (C, Ar), 115.6 (C, Ar), 122.3 (C, 
Ar), 125.1 (C, Ar), 127.5 (C, Ar), 127.6 (C, Ar), 130.8 (C, Ar), 133.5 (C, Ar), 143.4 (C, 
Ar), 143.8 (C=N), 148.3 (C, Ar), 149.6 (C, Ar), 160.5 (C-F), 162.9 (C-F), 167.1 (S-C=N). 
Anal. Calcd for C15H11FN4S: C, 60.39; H, 3.72; N, 18.78; S, 10.75; found: C, 60.37; H, 
3.74; N, 18.81; S, 10.77. HRMS (ESI): 299.0741 [M + H]+. 
4.4.6. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole (8) 
Crystallization from toluene/hexane 7:3, afforded orange crystals, Yield: 61%, m.p. (ºC): 
187. IR (KBr, cm-1): 1587 (C=N), 1610 (C=N), 3069 (N-H); 1H NMR (300 MHz, DMSO-
d6), δ ppm: 3.79 (s, 3H, CH3), 6.97 (d, J = 8.3 Hz, 2H, Ar), 7.29 (s, 1H, CH of thiazole), 
7.73 (t, J = 6.2 Hz, 1H, Ar), 7.78 (d, J = 8.3 Hz, 2H, Ar), 8.14 (d, J = 8.3 Hz, 1H, Ar), 8.17 
(s, 1H, CH), 8.32 (t, J = 7.8 Hz, 1H, Ar), 8.72 (d, J = 4.8 Hz, 1H, Ar), 12.15 (broad s, 1H, 
NH). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 55.2 (CH3), 103.3 (S-CH), 114.1 (C, Ar), 
122.1 (C, Ar), 124.9 (C, Ar), 126.9 (C, Ar), 134.3 (C, Ar), 143.2 (C, Ar), 144.1 (C, Ar), 
148.8 (C, Ar), 150.4 (C=N), 167.1 (S-C=N). Anal. Calcd for C16H14N4OS: C, 61.92; H, 
4.55; N, 18.05; S, 10.33; found: C, 61.90; H, 4.57; N, 18.08; S, 10.34. HRMS (ESI): 
311.0928 [M + H]+. 
4.4.7. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-chlorophenyl)-1,3-thiazole (9) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 74%, m.p. (ºC): 
226. IR (KBr, cm-1): 1552 (C=N), 1612 (C=N), 3030 (N-H); 1H NMR (400 MHz, DMSO-
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d6), δ ppm: 7.48 (d, J = 8.3 Hz, 2H, Ar), 7.75 (t, J = 6.1 Hz, 1H, Ar), 7.56 (s, 1H, CH of 
thiazole), 7.88 (d, J = 8.2 Hz, 2H, Ar), 8.16 (d, J = 8.1 Hz, 1H, Ar), 8.20 (s, 1H, CH), 8.33 
(t, J = 7.6 Hz, 1H, Ar), 8.43 (broad s, 1H, NH), 8.75 (d, J = 4.6 Hz, 1H, Ar). 13C NMR 
(75.5 MHz, DMSO-d6), δ ppm: 105.1 (S-CH), 119.4 (C, Ar), 123.7 (C, Ar), 127.2 (C, Ar), 
128.6 (C, Ar), 132.0 (C, Ar), 133.4 (C, Ar), 137.2 (C, Ar), 141.2 (C, Ar), 149.1 (C, Ar), 
149.4 (C, Ar), 152.8 (C=N), 167.8 (S-C=N). Anal. Calcd for C15H11ClN4S: C, 57.23; H, 
3.52; N, 17.80; S, 10.19; found: C, 57.24; H, 3.51; N, 17.82; S, 10.18. HR-MS (ESI): 
315.0441 [M + H]+. 
4.4.8. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole (10) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 68%, m.p. (ºC): 
211. IR (KBr, cm-1): 1551 (C=N), 1615 (C=N), 3058 (N-H). 1H NMR (300 MHz, DMSO-
d6), δ ppm: 7.52-7.91 (m, 5H, Ar), 8.15-8.82 (m, 4H, Ar), 12.18 (s,1H, NH). 13C NMR 
(75.5 MHz, DMSO-d6), δ ppm: 111.3 (S-CH), 121.9 (C, Ar), 125.3 (C, Ar), 126.3 (C, Ar), 
128.1 (C, Ar), 130.2 (C, Ar), 132.1 (C, Ar), 132.7 (C, Ar), 135.8 (C, Ar), 142.6 (C, Ar), 
144.2 (C, Ar), 146.5 (C, Ar), 149.8 (C=N), 166.9 (S-C=N). Anal. Calcd for C15H10Cl2N4S: 
C, 51.59; H, 2.89; N, 16.04; S, 9.18; found: C, 51.57; H, 2.86; N, 16.03; S, 9.15. HR-MS 
(ESI): 349.0144 [M + H]+. 
4.4.9. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(3,4-dichlorophenyl)-1,3-thiazole (11) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 59%, m.p. (ºC): 
217. IR (KBr, cm-1): 1563 (C=N), 1614 (C=N), 3154 (N-H). 1H NMR (400 MHz, DMSO-
d6), δ ppm:  5.22 (broad s,1H, NH), 7.54-7.88 (m, 5H, Ar), 8.15-8.71 (m, 4H, Ar); 13C 
NMR (100 MHz, DMSO-d6), δ ppm: 110.9 (S-CH), 121.6 (C, Ar), 124.9 (C, Ar), 127.5 (C, 
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Ar), 129.7 (C, Ar), 131.7 (C-Cl), 132.2 (C, Ar), 132.7 (C-Cl), 134.6 (C, Ar), 142.7 (C, Ar), 
143.9 (C, Ar), 146.0 (C, Ar), 149.0 (C=N), 166.4 (S-C=N). Anal. Calcd for C15H10Cl2N4S: 
C, 51.59; H, 2.89; N, 16.04; S, 9.18; found: C, 51.62; H, 2.85; N, 16.07; S, 9.20. HRMS 
(ESI): 349.0068 [M + H]+. 
4.4.10. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(3-nitrophenyl)-1,3-thiazole (12) 
Crystallization from toluene/hexane 7:3, afforded orange crystals, Yield: 31%, m.p. (ºC): 
226. IR (KBr, cm-1): 1355 (NO2), 1560 (C=N), 1596 (C=N), 3413 (N-H). 4.45 (broad s, 1H, 
NH), 7.67 (t, J = 6.5 Hz, 1H, Ar), 7.72 (t, J = 8.1 Hz, 1H, Ar), 7.81 (s, 1H, CH of thiazole), 
8.12 (d, J = 8.0 Hz, 1H, Ar), 8.16 (s, 1H, CH), 8.26 (t, J = 7.9 Hz, 1H, Ar), 8.31 (d, J = 7.9 
Hz, 1H, Ar), 8.67 (s, 1H, Ar), 8.72 (d, J = 4.8 Hz, 1H, Ar). 13C NMR (75.5 MHz, DMSO-
d6), δ ppm: 108.1 (S-CH), 119.9 (C, Ar), 121.9 (C, Ar), 125.0 (C, Ar), 130.3 (C, Ar), 131.6 
(C, Ar), 135.0 (C, Ar), 135.7 (C, Ar), 142.8 (C, Ar), 144.4 (C, Ar), 148.2 (C, Ar), 148.8 (C-
NO2), 167.4 (C=N). Anal. Calcd for C15H11N5O2S: C, 55.38; H, 3.41; N, 21.53; S, 9.86; 
found: C, 55.41; H, 3.39; N, 21.56; S, 9.88. HRMS (ESI): 326.0680 [M + H]+. 
4.4.11. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole (13) 
Crystallization from toluene/hexane 7:3, afforded orange crystals, Yield: 42%, m.p. (ºC): 
220. IR (KBr, cm-1): 1338 (NO2), 1539 (C=C), 1598 (C=N), 3148 (N-H). 1H NMR (300 
MHz, DMSO-d6), δ ppm: 4.74 (broad s, 1H, NH), 7.21 (t, J = 6.1 Hz, 1H, Ar), 7.50 (s, 1H, 
CH of thiazole), 7.74 (t, J = 7.9 Hz, 1H, Ar), 7.83 (d, J = 8.0 Hz, 2H, Ar), 7.98 (s, 1H, CH), 
8.07 (d, J = 9.0 Hz, 2H, Ar), 8.22 (d, J = 9.1 Hz, 2H, Ar), 8.47 (d, J = 4.9 Hz, 1H, Ar). 13C 
NMR (75.5 MHz, DMSO-d6), δ ppm: 110.0 (S-CH), 121.6 (C, Ar), 124.1 (C, Ar), 124.8 (C, 
Ar), 125.7 (C, Ar), 126.4 (C, Ar), 135.9 (C, Ar), 140.2 (CH2), 142.1 (C, Ar), 145.0 (C, Ar), 
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146.3 (C, Ar), 148.6 (C, Ar),149.3 (C-NO2), 167.6 (C=N) 168.9 (S-C=N). Anal. Calcd for 
C15H11N5O2S: C, 55.38; H, 3.41; N, 21.53; S, 9.86; found: C, 55.41; H, 3.46; N, 21.56; S, 
9.88. HRMS (ESI): 326.0696 [M + H]+. 
4.4.12. 2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(naphthalen-1-yl)-1,3-thiazole (14) 
Crystallization from toluene/hexane 7:3, afforded brown crystals, Yield: 87%, m.p. (ºC): 
216. IR (KBr, cm-1): 1540 (C=N), 1602 (C=N), 3112 (N-H). 1H NMR (400 MHz, DMSO-
d6), δ ppm: 7.31 (t, J = 6.0 Hz, 1H, Ar), 7.45 (s, 1H, CH of thiazole), 7.49 (d, J = 7.6 Hz, 
2H, Ar), 7.82 (t, J = 7.4 Hz, 1H, Ar), 7.94 – 7.85 (m, 5H, Ar), 8.00 (d, J = 8.6 Hz, 1H, Ar), 
8.07 (s, 1H, CH), 8.37 (broad s, 1H, NH), 8.54 (d, J = 4.9 Hz, 1H, Ar). 13C NMR (75.5 
MHz, DMSO-d6), δ ppm: 106.5 (S-CH), 122.5 (C, Ar), 123.8 (C, Ar), 124.2 (C, Ar), 125.2 
(C, Ar), 126.1 (C, Ar), 126.4 (C, Ar), 127.5 (C, Ar), 128.1 (C, Ar), 128.2 (C, Ar), 131.5 (C, 
Ar), 132.5 (C, Ar), 132.7 (C, Ar), 133.0 (C, Ar), 142.8 (CH2), 144.4 (C, Ar), 147.7 (C, Ar), 
150.5 (C=N), 167.0 (S-C=N). Anal. Calcd for C19H14N4S: C, 69.07; H, 4.27; N, 16.96; S, 
9.70; found: C, 69.09; H, 4.24; N, 16.94; S, 9.73. HRMS (ESI): 331.1007 [M + H]+. 
4.4.13. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-phenyl-1,3-thiazole (15) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 79%; m.p. (ºC): 
151. IR (KBr, cm-1): 1575 (C=N), 1615 (C=N), 3058 (N-H). 1H NMR (400 MHz, DMSO-
d6), δ ppm: 2.43 (s, 3H, CH3), 5.53 (broad s, 1H, NH), 7.30 (t, J = 7.4 Hz, 1H, Ar), 7.39 (t, 
J = 7.4 Hz, 2H, Ar), 7.44 (s, 1H, CH of thiazole), 7.76 (t, J = 6.5 Hz, 1H, Ar), 7.85 (d, J = 
7.6 Hz, 2H, Ar), 8.23 (d, J = 8.3 Hz, 1H, Ar), 8.35 (t, J = 8.0 Hz, 1H, Ar), 8.73 (d, J = 5.5 
Hz, 1H, Ar). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 13.4 (CH3), 105.9 (S-CH), 123.6 (C, 
Ar), 125.6 (C, Ar), 126.0 (C, Ar), 128.4 (C, Ar), 129.2 (C, Ar), 134.2 (C, Ar), 141.0 (C, 
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Ar), 143.9 (C, Ar), 144.6 (C, Ar), 147.5 (C, Ar), 150.0 (C=N), 168.9 (S-C=N). Anal. Calcd 
for C16H14N4S: C, 65.28; H, 4.79; N, 19.03; S, 10.89; found: C, 65.31; H, 4.82; N, 19.06; S, 
10.87. HRMS (ESI): 295.0985 [M + H]+. 
4.4.14. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole (16) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 68%, m.p. (ºC): 
143. IR (KBr, cm-1): 1496 (C=N), 1613 (C=N), 3058 (N-H). 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.31 (s, 3H, CH3), 2.39 (s, 3H, CH3), 3.84 (broad s, 1H, NH), 7.21 (d, J = 8.0 
Hz, 2H, Ar), 7.28 (s, 1H, CH of thiazole), 7.35 (t, J = 6.1 Hz, 1H, Ar), 7.76 (d, J = 8.1 Hz, 
2H, Ar), 7.83 (t, J = 7.8 Hz, 1H, Ar), 8.02 (d, J = 8.1 Hz, 1H, Ar), 8.57 (d, J = 4.2 Hz, 1H, 
Ar). 13C NMR (75.5 MHz, DMSO-d6): 12.7 (CH3), 20.7 (CH3), 103.9 (S-CH), 121.7 (C, 
Ar), 124.4 (C, Ar), 125.8 (C, Ar), 129.1 (C, Ar), 136.9 (C, Ar), 141.0 (C, Ar), 143.6 (C, 
Ar), 145.3 (C, Ar), 148.3 (Ar), 151.7 (C=N), 168.9 (S-C=N). Anal. Calcd for C17H16N4S: 
C, 66.21; H, 5.23; N, 18.17; S, 10.40; found: C, 66.26; H, 5.26; N, 18.18; S, 10.39. HR-MS 
(ESI): 309.7527 [M + H]+. 
4.4.15. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(4-bromophenyl)-1,3-thiazole (17) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 61%, m.p. (ºC): 
202. IR (KBr, cm-1): 1567 (C=N), 1615 (C=N), 3029 (N-H).  1H NMR (400 MHz, DMSO-
d6), δ ppm: 2.39 (s, 3H, CH3), 7.36 (t, J = 6.3 Hz, 1H, Ar), 7.45 (s, 1H, CH of thiazole), 
7.60 (d, J = 8.6 Hz, 2H, Ar), 7.87-7.81 (m, 4H, Ar), 8.02 (d, J = 8.1 Hz, 1H, Ar), 8.57 (d, J 
= 4.8 Hz, 1H, Ar), 10.33 (broad s, 1H, NH). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 12.7 
(CH3), 105.8 (S-CH), 120.0 (C, Ar), 121.0 (C, Ar), 123.9 (C, Ar), 127.4 (C, Ar), 128.0 (C, 
Ar), 132.0 (C, Ar), 134.4 (C, Ar), 137.1 (C, Ar), 147.6 (C, Ar), 149.0 (C, Ar), 155.3 (C=N), 
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170.0 (S-C=N). Anal. Calcd for C16H13BrN4S: C, 51.48; H, 3.51; N, 15.01; S, 8.59; found: 
C, 51.51; H, 3.54; N, 15.04; S, 8.56. HRMS (ESI): 373.8177 [M + H]+. 
4.4.16. 5-methyl-(2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(4-bromophenyl)-1,3-thiazole 
(18) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 52%, m.p. (ºC): 
198. IR (KBr, cm-1): 1565 (C=N), 1604 (C=N), 3164 (N-H). 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.33 (s, 3H, CH3), 2.40 (s, 3H, CH3), 7.28 (t, J = 6.0 Hz, 1H, Ar), 7.60 – 7.57 
(m, 4H, Ar), 7.77 (t, J = 7.7 Hz, 1H, Ar), 7.99 (d, J = 8.0 Hz, 1H, Ar), 8.52 (d, J = 4.0 Hz, 
1H, Ar), 8.81 (broad s, 1H, NH). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 12.6 (CH3), 
12.7 (CH3), 119.0 (S-CH), 119.9 (C, Ar), 120.6 (C, Ar), 123.7 (C, Ar), 130.3 (C, Ar), 131.7 
(C, Ar), 134.8 (C, Ar), 136.9 (C, Ar), 155.4 (C, Ar), 149.0 (C=N), 166.0 (S-C=N). Anal. 
Calcd for C17H15BrN4S: C, 52.72; H, 3.90; N, 14.47; S, 8.28; found: C, 52.75; H, 3.94; N, 
14.45; S, 8.26. HRMS (ESI): 387.8449 [M + H]+. 
4.4.17. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole (19) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 73%, m.p. (ºC): 
209. IR (KBr, cm-1): 1560 (C=N), 3060 (N-H). 1H NMR (300 MHz, DMSO-d6), δ ppm: 
2.42 (s, 3H, CH3), 6.07 (broad s, 1H, NH), 7.25 (d, J = 8.6, 5.6 Hz, 2H, Ar), 7.40 (s, 1H, 
CH of thiazole), 7.57 (t, J = 5.0 Hz, 1H, Ar), 7.91 (dd, J = 8.6, 5.6 Hz, 2H, Ar), 8.12 (d, J = 
8.0 Hz, 1H, Ar), 8.13 (t, J = 7.2 Hz, 1H, Ar), 8.65 (d, J = 5.0 Hz, 1H, Ar). 13C NMR (75.5 
MHz, DMSO-d6), δ ppm: 12.4 (CH3), 104.4 (S-CH), 115.4 (C, Ar), 120.2 (C, Ar), 123.7 (C, 
Ar), 127.5 (C, Ar), 131.2 (C, Ar), 137.8 (C, Ar), 146.0 (C, Ar), 147.7 (C, Ar), 154.0 (C, 
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Ar), 160.0 (C=N), 169.3 (S-C=N). Anal. Calcd for C16H13FN4S: C, 61.52; H, 4.19; N, 
17.94; S, 10.27; found: C, 61.57; H, 4.21; N, 17.95; S, 10.30. HRMS (ESI): [M + H]+. 
4.4.18. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole (20) 
Crystallization from toluene/hexane 7:3, afforded orange crystals, Yield: 58%, m.p. (ºC): 
216. IR (KBr, cm-1): 1496 (C=C), 1610 (C=N), 3359 (N-H). 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.42 (s, 3H, CH3), 3.78 (s, 3H, CH3), 7.25 (s, 1H, S-CH), 6.98-7.93 (m, 4H, Ar), 
8.19-8.83 (m, 4H, Ar), 10.90 (broad s,1H, NH). 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 
12.7 (CH3), 55.1 (CH3), 102.7 (S-CH), 114.0 (C, Ar), 121.7 (C, Ar), 124.4 (C, Ar), 124.5 
(C, Ar), 125.9. (C, Ar), 126.9 (C, Ar), 143.6 (C, Ar), 145.4 (C, Ar), 158.9 (C=N), 169.5 (S-
C=N). Anal. Calcd for C17H16N4OS: C, 62.94; H, 4.97; N, 17.27; S, 9.88; found: C, 62.91; 
H, 4.95; N, 17.28; S, 9.90. HR-MS (ESI): 325.0975 [M + H]+. 
4.4.19. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(4-chlorophenyl)-1,3-thiazole (21) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 73%, m.p. (ºC): 
222. IR (KBr, cm-1): 1574 (C=N), 1603 (C=N), 3359 (N-H). 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.39 (s, 3H, CH3), 7.35 (t, J = 5.9 Hz, 1H, Ar), 7.42 (s, 1H, CH of thiazole), 
7.46 (d, J = 8.4 Hz, 2H, Ar), 7.83 (t, J = 7.8 Hz, 1H, Ar), 7.89 (d, J = 8.4 Hz, 2H, Ar), 8.02 
(d, J = 8.0 Hz, 1H, Ar), 8.56 (d, J = 4.2 Hz, 1H, Ar), 11.45 (broad s, 1H, NH). 13C NMR 
(75.5 MHz, DMSO-d6), δ ppm: 13.4 (CH3), 106.5 (S-CH), 122.6 (C, Ar), 125.3 (C, Ar), 
127.7 (C, Ar), 129.2 (C, Ar), 132.6 (C, Ar), 133.6 (C, Ar), 143.0 (C, Ar), 145.5 (C, Ar), 
151.7 (C=N), 169.4 (S-C=N). Anal. Calcd for C16H13ClN4S: C, 58.44; H, 3.98; N, 17.04; S, 
9.75; found: C, 58.47; H, 3.95; N, 17.09; S, 9.71. HR-MS (ESI): 329.8148 [M + H]+. 
4.4.20. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole (22) 
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Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 62%, m.p. (ºC): 
227; IR (KBr, cm-1): 1521 (C=N), 1609 (C=N), 3058 (N-H). 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.43 (s, 3H, CH3,), 4.04 (broad s,1H, NH), 7.43 (s, 1H, CH of thiazole), 7.32-
7.88 (m, 3H, Ar), 8.19-8.69 (m, 4H, Ar); 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 12.8 
(CH3), 105.0 (S-CH), 124.4 (C, Ar), 125.5 (C, Ar), 127.7 (C, Ar), 128.6 (C, Ar), 134.2 (C, 
Ar), 141.2 (C, Ar), 143.1 (C, Ar), 145.4 (C, Ar), 151.7 (C=N), 169.0 (S-C=N). Anal. Calcd 
for C16H12Cl2N4S: C, 52.90; H, 3.33; N, 15.42; S, 8.83; found: C, 52.93; H, 3.35; N, 15.47; 
S, 8.84. HR-MS (ESI): 362.9432 [M + H]+. 
4.4.21. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(3,4-dichlorophenyl)-1,3-thiazole (23) 
Crystallization from toluene/hexane 7:3, afforded yellow crystals, Yield: 69%, m.p. (ºC): 
209. IR (KBr, cm-1): 1554 (C=N), 1614 (C=N), 3061 (N-H); 1H NMR (300 MHz, DMSO-
d6), δ ppm: 2.43 (s, 3H, CH3,), 4.12 (broad s,1H, NH), 7.48 (s, 1H, CH of thiazole), 7.29-
7.83 (m, 3H, Ar), 8.12-8.63 (m, 4H, Ar); 13C NMR (75.5 MHz, DMSO-d6), δ ppm: 12.8 
(CH3), 110.4 (S-CH), 121.3 (C, Ar), 124.3 (C, Ar), 127.4 (C, Ar), 128.6 (C, Ar), 145.4 (C, 
Ar), 145.8 (C, Ar), 146.3 (C, Ar), 152.2 (C, Ar), 158.1 (C=N), 169.4 (S-C=N). Anal. Calcd 
for C16H12Cl2N4S: C, 52.90; H, 3.33; N, 15.42; S, 8.83; found: C, 52.89; H, 3.31; N, 15.43; 
S, 8.80. HR-MS (ESI): 363.0220 [M + H]+. 
4.4.22. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(3-nitrophenyl)-1,3-thiazole (24) 
Crystallization from toluene/hexane 7:3, afforded orange crystals, Yield: 49%, m.p. (ºC): 
229. IR (KBr, cm-1): 1345 (NO2), 1453 (C=C), 1601 (C=N), 3054 (N-H). 1H NMR (300 
MHz, DMSO-d6), δ ppm: 2.43 (s, 3H, CH3,), 4.11(bs, 1H, NH), 7.47 (s, 1H, S-CH), 7.38-
7.91 (m, 4H, Ar), 8.15-8.71 (m, 4H, Ar). 13C NMR (100 MHz, DMSO-d6), δ ppm: 12.8 
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(CH3), 107.8 (C, Ar), 119.9 (C, Ar), 121.7 (C, Ar), 122.1 (C, Ar), 124.5 (C, Ar), 130.2 (C, 
Ar), 131.5 (C, Ar), 135.9 (C, Ar), 138.6 (C, Ar), 141.1 (C, Ar), 145.5 (C, Ar), 147.5 (C=N), 
148.2 (C-NO2), 169.0 (S-C=N). Anal. Calcd for C16H13N5O2S: C, 56.63; H, 3.86; N, 20.64; 
S, 9.45; found: C, 56.65; H, 3.89; N, 20.67; S, 9.48. HR-MS (ESI): 340.0851 [M + H]+. 
4.4.23. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole (25) 
Crystallization from toluene/hexane 7:3, afforded orange crystals, Yield: 58%, m.p. (ºC): 
245. IR (KBr, cm-1): 1577 (C=N), 1596 (C=N), 3342 (N-H). 1H NMR (400 MHz, DMSO-
d6), δ ppm: 2.37 (s, 3H, CH3), 7.30 (t, J = 6.2 Hz, 1H, Ar), 7.63 (s, 1H, CH of thiazole), 
7.74 (broad s, 1H, NH), 7.79 (t, J = 7.4 Hz, 1H, Ar), 8.02 (d, J = 8.1 Hz, 1H, Ar), 8.10 (d, J 
= 9.0 Hz, 2H, Ar), 8.25 (d, J = 9.0 Hz, 2H, Ar), 8.53 (d, J = 4.8 Hz, 1H, Ar). 13C NMR 
(75.5 MHz, DMSO-d6), δ ppm: 12.4 (CH3), 108.6 (S-CH), 119.4 (C, Ar), 122.9 (C, Ar), 
124.2 (C, Ar), 126.3 (C, Ar), 136.4 (C, Ar), 141.2 (C, Ar), 146.1 (C, Ar), 148.6 (C, Ar), 
155.5 (C=N), 172.0 (S-C=N). Anal. Calcd for C16H13N5O2S: C, 56.63; H, 3.86; N, 20.64; S, 
9.45; found: C, 56.67; H, 3.87; N, 20.65; S, 9.48. HR-MS (ESI): 340.0683 [M + H]+. 
4.4.24. (2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-(naphthalen-1-yl)-1,3-thiazole (26) 
Crystallization from toluene/hexane 7:3, afforded brown crystals, Yield: 89%, m.p. (ºC): 
203. IR (KBr, cm-1): 1556 (C=N), 1614 (C=N), 3035 (N-H); 1H NMR (300 MHz, DMSO-
d6), δ ppm: 1.70 (s, 3H, CH3), 3.66 (broad s,1H, NH), 7.48 (s, 1H, CH of thiazole), 7.30-
7.52 (m, 4H, Ar), 7.81-8.00 (m, 6H, Ar), 8.55 (d, J = 4.9 Hz, 1H, Ar); 13C NMR (75.5 
MHz, DMSO-d6), δ ppm: 24.0 (CH3), 104.5 (S-CH), 119.0 (C, Ar), 124.0 (C, Ar), 124.1 (C, 
Ar), 126.4 (C, Ar), 127.6 (C, Ar), 128.0 (C, Ar), 128.1 (C, Ar), 136.7 (C, Ar), 144.3 (C, 
Ar), 149.4 (C, Ar), 150.3 (C, Ar), 153.7 (C=N), 169.3 (S-C=N). Anal. Calcd for 
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C20H16N4S: C, 69.74; H, 4.68; N, 16.27; S, 9.31; found: C, 69.70; H, 4.70; N, 16.31; S, 
9.34. HR-MS (ESI): 345.1143 [M + H]+. 
4.5. Cruzain inhibition 
Recombinant cruzain was gently provided by Alison Doak and Dr. Brian Shoichet, from 
the University of California San Francisco. Cruzain activity was measured as previously 
described[26], by monitoring the cleavage of the fluorogenic substrate Z-Phe-Arg-
aminomethylcoumarin (Z-FR-AMC) in a Synergy 2 fluorimeter (Biotek), from the Center 
of Flow Cytometry and Fluorimetry at the Biochemistry and Immunology Department 
(UFMG), using filters of 340 nm for excitation and 440 nm for emission. All assays were 
performed in sodium acetate 0.1M pH 5.5 and in the presence of 5 mM dithiothreitol (DTT) 
and 0.01% Triton X-100, in a final volume of 200 µL and on a 96 well plate format. The 
final concentration of cruzain was 0.5 nM, and the substrate concentration was 2.5 µM (Km 
= 1 µM). In all assays, enzyme inhibition was measured after a 10-minute pre-incubation of 
the compounds with enzyme. Compounds were initially screened at 100 µM, unless they 
were insoluble at this concentration, in which cases they were tested at 75 µM or 50 µM. If 
cruzain inhibition higher than 70% was observed at the original screening, IC50 was 
determined based on at least seven inhibitor concentrations, always after pre-incubation 
with cruzain for 10 minutes. All assays were performed in at least two independent 
experiments, each one in triplicates, and were followed for 5 min. Activity was calculated 
based on comparison to a DMSO control. Data was analyzed with Prism 5.0 (GraphPad). 
4.6. Parasites 
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Epimastigotes of T. cruzi (Y strain) were maintained at 26 °C in LIT medium (Liver 
Infusion Tryptose) supplemented with 10% fetal bovine serum (FBS) (Cultilab, Campinas, 
SP, Brazil), 1% hemin (Sigma Co, St. Louis, MO, USA), 1% R9 medium (Sigma Co), and 
50 µg/mL gentamycin (Novafarma, Anápolis, GO, Brazil). Bloodstream trypomastigotes 
forms of T. cruzi were obtained from supernatants of LLC-MK2 cells previously infected 
and maintained in RPMI-1640 medium (Sigma Co) supplemented with 10% FBS, and 50 
µg/mL gentamycin at 37 °C and 5% CO2. 
4.7. Cytotoxicity for HepG2 
The HepG2 cytotoxicity assay was adapted from Ballell et al.[27]. Actively growing 
HepG2 cells were removed from a T-175 TC flask using supplemented Eagle’s MEM and 
plated at a density of 3000 cells/well into the 384-well clear-bottom plates using a 
Multidrop instrument. Prior to addition of the cell suspension, the screening compounds 
(250 nL) were dispensed into the plates with an Echo 555 instrument. Plates were allowed 
to incubate at 37ºC at 80% relative humidity for 48 hours under 5% CO2. The signal 
developer, CellTiter-Glo (Promega) was added to the plates using a Multidrop and the 
plates were read using a ViewLux instrument (PerkinElmer). 
4.8. Antiproliferative activity for epimastigotes 
Epimastigotes were counted in a hemocytometer and then dispensed into 96-well plates at a 
cell density of 106 cells/well. Test inhibitors, dissolved in DMSO, were diluted into five 
different concentrations (1.23, 3.70, 11.11, 33.33, and 100 µg/mL) and added to the 
respective wells in triplicate. The plate was incubated for 11 days at 26 °C, and aliquots of 
each well were collected and the number of viable parasites were counted in a Neubauer 
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chamber, and compared to untreated parasite culture. IC50 values were calculated using 
non-linear regression on Prism 4.0 GraphPad software. This experiment was done in 
duplicate, and Benznidazole (LAFEPE, Brazil) were used as the reference inhibitors.  
4.9. Toxicity for Y strain trypomastigotes 
Trypomastigotes collected from the supernatant of LLC-MK2 cells were dispensed into 96-
well plates at a cell density of 4x105 cells/well. Test inhibitors, dissolved in DMSO, were 
diluted into five different concentrations and added into their respective wells, and the plate 
was incubated for 24h at 37 ºC and 5% of CO2. Aliquots of each well were collected and 
the number of viable parasites, based on parasite motility, was assessed in a Neubauer 
chamber. The percentage of inhibition was calculated in relation to untreated cultures. IC50 
calculation was also carried out using non-linear regression with Prism 4.0 GraphPad 
software. Benznidazole was used as the reference drug. 
4.10. Docking studies 
The structures of all compounds were obtained by application of the RM1[34] method, 
available as part of the SPARTAN 08’ program[35], using internal default settings for 
convergence criteria. Docking calculations and analysis was carried using the T. cruzi 
cruzain (PDB ID code: 3IUT) as the target[30], in which there was a cocrystallized 
complex with an inhibitor (referred to as “KB2”). The active site was defined as all atoms 
within a radius of 6.0 Å from this cocrystallized ligand. The residues GLN19, CYS25, 
SER61, LEU67, MET68, ASN70, ASP161, HIS162, TRP184 and GLU208 were treated as 
flexible. The GOLD 5.1 program[36] was used for docking calculations, followed by 
Binana program[37], which was used to analyse the molecular interactions present in the 
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best docking solutions, using default setting, except for hydrogen bond distance (changed 
to a maximum of 3.5 Å). Figures were generated with Pymol[38]. 
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LIST OF CAPTIONS 
Figure 1. Structures of nifurtimox and benznidazole. 
 
Scheme 1: Synthetic procedures for thiosemicarbazones (2a-b) and 2-(pyridin-2-yl)-1,3-
thiazoles (3-26). Reagents and conditions: (a) thiosemicarbazide, 2-propanol, acetic acid (3 
drops), ultrasound irradiation, r.t., 120 min; (b) substituted 2-bromoacetophenones, 2-
propanol, CaCO3, ultrasound irradiation, r.t., 60 min; *R: H for all compounds, except to 
(6) and (18) where R: Me. 
 
Figure 2. ORTEP view of compound (4) showing intramolecular H-bonding (30% 
probability ellipsoids are shown). 
 
Table 1: Crystal data and structure refinement for compound (4). 
 
Table 2: Anti T. cruzi activities of acetylpyridin-2-yl thiosemicarbazone (2a) and 2-
(pyridin-2-yl)-1,3-thiazoles (3-14). 
 
Table 3: Anti T. cruzi Activities of acetylpyridin-2-yl thiosemicarbazone (2b) and 2-
(pyridin-2-yl)-1,3-thiazoles (15-26). 
 
Figure 3: Summary of SAR of trypanocidal activity for compounds (3-26). 
 
Table 4: Comparison of in vitro cruzain inhibition activity of compounds (2a-2b) and (3-
26). 
 
Figure 4: Superposition of the docking solutions for cruzain-inhibiting compounds (5), 
(12), (15), (16), (19), (20), (22), (23) and (26) (blue structures) bound to cruzain (green) 
and the crystallographic structure of the “KB2” cocrystallized ligand[30] (red structure). 
 
Figure 5: Trend observed between the in vitro (pIC50 for cruzain inhibition) and in silico 
(docking score) results, for compounds (5), (12), (15), (16), (19), (20), (22), (23) and (26). 
 
Figure 6: Detailed view of the docking solutions for (A) compound (5) and (B) compound 
(26). Hydrophobic interactions (green) and hydrogen bonds (cyan). 
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Table 5: Docking scores and molecular interactions between cruzain and molecules (5) and 
(26).α 
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TABLE 1 
Empirical formula C16 H14 N4 S 
Formula weight  294.37 
Temperature (K) 296(2)  
Wavelength (Å) 0.71073 
Crystal system  Orthorhombic 
Space group  Pna21 
Unit cell dimensions  
a (Å) 9.858(1)  
b (Å) 25.602(3) 
c (Å) 5.5127(6) 
Volume (Å3) 1391.3(3)  
Z 4 
ρcalc (g cm-3) 1.405  
µ (mm-1) 0.231  
F(000) 616 
Crystal size (mm) 0.6 x 0.1 x 0.1  
θ range (°) 3.2 to 25.0 
Reflections collected 5864 
Independent reflections 2635 
Observed reflections [I > 2σ(I)] 1489 
Rint  0.0590 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2635 / 1 / 191 
Goodness-of-fit on F2 0.997 
R [I > 2σ(I)] 0.0580 
wR2 (all data) 0.0871 
Absolute structure parameter -0.03(11) 
Residual extrema (e Å-3) 0.183 and -0.144  
CCDC number 980106 
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TABLE 2 
 
compd. Ar Y strain T. cruzi, IC50 (µM) HepG2, IC50  trypomastigotesa epimastigotesb (µM)c 
 
 
2a --- 17.3 119.5 ND 
3 Ph 5.4 8.3 100 
4 4-CH3Ph 16.8 3.8 100 
5 4-BrPh 2.2 2.2 100 
6 4-BrPh* 2.6 18.3 100 
7 4-FPh 72.7 3.5 18.20 
8 4-CH3OPh 4.8 5.6 100 
9 4-ClPh 3.8 3.8 100 
10 2,4-diClPh 1.2 4.8 100 
11 3,4-diClPh 1.2 4 100 
12 3-NO2Ph 74.2 2.5 100 
13 4-NO2Ph 152.9 4.4 100 
14 2-Naphthyl 2.1 8.3 100 
Bdz --- 6.2 6.6 ND 
a
 Determined 24 h after incubation of trypomastigotes with the compounds. b Determined 11 days after 
incubation of epimastigotes with the compounds. IC50 was calculated from at least five concentrations, in 
triplicate (SD < 10%). c IC50 determined for human Hepg2 after 48 h of incubation in the presence of the 
compounds. *R: Methyl, see Scheme 1. Bdz: benznidazole. ND: not determined. 
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TABLE 3 
compd. Ar Y strain T. cruzi, IC50 (µM) HepG2, IC50 trypomastigotesa epimastigotesb (µM)c 
 
2b --- 2.8 4.5 ND 
15 Ph 1.1 2.7 91.20 
16 4-CH3Ph 1.7 2.5 100 
17 4-BrPh 2.1 2.1 100 
18 4-BrPh* 2.3 2.3 85.11 
19 4-FPh 3.8 2.8 91.20 
20 4-CH3OPh 2.1 14.7 100 
21 4-ClPh 2.1 2.5 100 
22 2,4-diClPh 1.9 14.9 100 
23 3,4-diClPh 3.1 5.0 100 
24 3-NO2Ph 3.9 2.4 100 
25 4-NO2Ph 36.7 5.2 100 
26 2-Naphthyl 2.0 4.1 100 
Bdz --- 6.2 6.6 ND 
a
 Determined 24 h after incubation of trypomastigotes with the compounds. b Determined 11 days after 
incubation of epimastigotes with the compounds. IC50 was calculated from at least five concentrations, in 
triplicate (SD < 10%). c IC50 determined for human Hepg2 after 48 h of incubation in the presence of the 
compounds. *R: Methyl, see Scheme 1. Bdz: benznidazole. Percentage of inhibition is the average of triplicate 
runs determined in one experiment. ND: not determined. 
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TABLE 4 
Compd. Ar % cruzain inhibition at 100µMa IC50 (µM) 
 
2a  1 ± 2 ND 
2b  5 ± 5 ND 
 
3 Ph 9 ± 1b ND 
15 Ph 93 ± 3 1.3 ± 0.7 
4 4-CH3Ph 23 ± 2 ND 
16 4-CH3Ph 90 ± 4 0.4 ± 0.2 
5 4-BrPh 86 ± 6 9.5 ± 7.5 
17 4-BrPh -8 ± 2 ND 
6 4-BrPh* 10 ± 4 ND 
18 4-BrPh* 27 ± 3 ND 
7 4-FPh 22 ± 3c ND 
19 4-FPh 89 ± 5 0.3 ± 0.2 
8 4-CH3OPh 20 ± 1b ND 
20 4-CH3OPh 95 ± 2 0.04 ± 0.03 
9 4-ClPh -1 ± 4b ND 
21 4-ClPh -3 ± 1 ND 
10 2,4-diClPh 0 ± 3b ND 
22 2,4-diClPh 81 ± 7 4.8 ± 3.8 
11 3,4-diClPh 21 ± 9 ND 
23 3,4-diClPh 89 ± 4 0.4 ± 0.1 
12 3-NO2Ph 85 ± 2 1.3 ± 0.7 
24 3-NO2Ph 10 ± 5b ND 
13 4-NO2Ph 12 ± 3 ND 
25 4-NO2Ph 11 ± 5b ND 
14 2-Naphthyl 3 ± 1 ND 
26 2-Naphthyl 94 ± 3 0.01 
aValues correspond to the average of six measurements, from two independent experiments, each one in 
triplicate. Errors are given by the ration between the standard deviation and the square root of the number of 
measurements. Compounds evaluated at 100 µM unless otherwise noted. bCompounds evaluated  at 75 µM. 
cCompounds evaluated  at 50 µM. dIC50 determinations were performed at least twice, each based on at least 
seven compound concentrations in triplicates. *R: Methyl, see Scheme 1. ND: not determined. 
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TABLE 5 
 
Cruzain Residues Molecules 5 26 
CYS22 - HC 
GLY23 HC HC 
CYS25 - 3.4 
TRP26 HC HC 
SER64 HC - 
LEU67 HC HC 
MET68 HC HC 
ALA138 HC HC 
LEU160 - HC 
ASP161 2.8 2.5 
HIS162 - HC 
SCORES 55.29 66.09 
αHC means “Hydrophobic Contacts” and the numbers are the hydrogen bond distances, in Ångstroms. 
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SCHEME 1 
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HIGHLIGHTS 
 
20 compounds showed good inhibition levels on the trypomastigote form of the parasite. 
9 compounds inhibited cruzain enzyme with IC50 0.01-9.5 µM. 
None of the compounds tested shown cytotoxicity. 
The hybridization of 2-pyridine and 1,3-thiazole achieved potent trypanocidal activity. 
Docking studies corroborated with binding results on cruzain. 
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0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)
L1118_11.1h
Marcos Verissimo
Amostra P
Solicitacao N. L1118-11
05.12.2013
9 (s)
11.63
3 (d)
8.55
12 (s)
8.35
6 (d)
8.26
12 (s)
8.16
7 (s)
8.09
1 (t)
7.81
2 (t)
7.35
1
2
3
N
4
5
6 7
N
8
NH
9 10
S
11
NH212
1H NMR (300 MHz, dmso) δ 11.63 (s, 1H), 8.55 (d, J = 4.9 Hz, 1H), 
8.35 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.16 (s, 1H), 8.09 (s, 1H), 
7.81 (t, J = 7.7 Hz, 1H), 7.35 (t, J = 4.9 Hz, 1H).
2-(Pyridin-2-ylmethylene)hydrazinecarbothioamide (2a) 
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6.76.86.97.07.17.27.37.47.57.67.77.87.98.08.18.28.38.48.58.68.78.88.99.09.1
f1 (ppm)
AF
14-05-12
2 (t)
7.37
1 (t)
7.77
11 (s)
8.12
6 (d)
8.41
3 (d)
8.56
11 (s)
8.37
1
2
3
N
4
5
6 7
N
8
NH
9 10
NH211
S
12
CH313
1H NMR (300 MHz, DMSO) δ 10.30 (s, 1H), 8.56 (d, J = 5.5 
Hz, 1H), 8.41 (d, J = 8.1 Hz, 2H), 8.39 – 8.35 (m, 1H), 8.12 (s, 
1H), 7.77 (t, J = 7.8 Hz, 1H), 7.37 (t, J = 6.1 Hz, 1H), 2.37 (s, 
3H).
2-[1-(2-Pyridinyl)ethylidene]hydrazinecarbothioamide (2b)
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102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
L1118_11.13c
Marcos Verissimo
Amostra P
Solicitacao N. L1118-11
05.12.2013
12
0.
18
12
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05
13
6.
48
14
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49
14
9.
23
15
3.
26
17
8.
33
1
2
3
N
4
5
6 7
N
8
NH
9 10
S
11
NH212
13C NMR (75 MHz, dmso) δ 178.33, 153.26, 149.23, 142.49, 
136.48, 124.05, 120.18.
2-(Pyridin-2-ylmethylene)hydrazinecarbothioamide (2a) 
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102030405060708090100110120130140150160170180190200210
f1 (ppm)
APT-2
APT02 29-06-12 
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CH313
2-[1-(2-Pyridinyl)ethylidene]hydrazinecarbothioamide (2b)
13C NMR (101 MHz, DMSO) δ 179.09, 154.61, 148.35, 148.09, 136.51, 
123.98, 120.96, 12.12.
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0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)
L1118_1.1h
Marcos Verissimo
Amostra TP-4-F
Solicitacao N. L1118-1
04.12.2013
3 (d)
8.70
2 (t)
8.21
7 (s)
8.15
6 (d)
8.08
20 (t)
7.91
1 (t)
7.65
13 (s)
7.45
19 (t)
7.25
9 (s)
4.92
2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole (7)1
2
3
N
4
5
6 7
N
8
NH
9 10
N
11 12
13
S
14
15
16
17 18
19
20
F
21
1H NMR (300 MHz, dmso) δ 8.70 (d, J = 5.0 Hz, 1H), 8.21 (t, J = 7.5 
Hz, 1H), 8.15 (s, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.91 (t, J = 6.3 Hz, 2H), 
7.65 (t, J = 6.3 Hz, 1H), 7.45 (s, 1H), 7.25 (t, J = 8.9 Hz, 2H), 4.92 (s, 
3H).
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6.97.07.17.27.37.47.57.67.77.87.98.08.18.28.38.48.58.68.78.88.99.09.1
f1 (ppm)
L1118_1.1h
Marcos Verissimo
Amostra TP-4-F
Solicitacao N. L1118-1
04.12.2013
3 (d)
8.70
2 (t)
8.21
7 (s)
8.15
6 (d)
8.08
20 (t)
7.91
1 (t)
7.65
13 (s)
7.45
19 (t)
7.25
2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole (7)1
2
3
N
4
5
6 7
N
8
NH
9 10
N
11 12
13
S
14
15
16
17 18
19
20
F
21
1H NMR (300 MHz, dmso) δ 8.70 (d, J = 5.0 Hz, 1H), 8.21 (t, J = 7.5 
Hz, 1H), 8.15 (s, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.91 (t, J = 6.3 Hz, 2H), 
7.65 (t, J = 6.3 Hz, 1H), 7.45 (s, 1H), 7.25 (t, J = 8.9 Hz, 2H), 4.92 (s, 
3H).
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0102030405060708090100110120130140150160170180190200
f1 (ppm)
J1125_30.13c
Marcos Cardoso
Amostra TP-07
Solicitacao N. J1125-30
11.01.12   UFPE
10
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44
11
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12
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2-(2-(pyridin-2-ylmethylene)hydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole (7)
1
2
3
N
4
5
6 7
N
8
NH
9 10
N
11 12
13
S
14
15
16
17 18
19
20
F
21
13C NMR (101 MHz, dmso) δ 167.09, 162.94, 160.51, 149.60, 148.28, 
143.84, 143.45, 133.53, 130.81, 127.63, 127.55, 125.10, 122.30, 115.65, 
115.44, 105.38.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)
J1125_36.1h
Marcos Cardoso
Amostra R-TAP-01
Solicitacao N. J1125-36
27.01.2012  UFPE
3 (d)
8.73
1 (t)
8.35
6 (d)
8.23
16,20 (d)
7.85
2 (t)
7.76
18 (t)
7.30
21 (s)
2.43
13 (s)
7.44
17,19 (d)
7.40
9 (s)
5.53
1
2
3
N
4
5
6 7
N
8
NH
9 10
N
11 12
13
S
14
15
16
17 18
19
20
CH321
(2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-phenyl-1,3-thiazole (15)
1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 5.5 Hz, 
1H), 8.35 (t, J = 7.9 Hz, 1H), 8.23 (d, J = 8.3 Hz, 1H), 
7.85 (d, J = 7.6 Hz, 2H), 7.76 (t, J = 6.5 Hz, 1H), 7.44 (s, 
1H), 7.39 (d, J = 7.3 Hz, 1H), 7.30 (t, J = 7.4 Hz, 1H).
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7.17.27.37.47.57.67.77.87.98.08.18.28.38.48.58.68.78.8
f1 (ppm)
J1125_36.1h
Marcos Cardoso
Amostra R-TAP-01
Solicitacao N. J1125-36
27.01.2012  UFPE
3 (d)
8.73
1 (t)
8.35
6 (d)
8.23
16,20 (d)
7.85
2 (t)
7.76
18 (t)
7.30
13 (s)
7.44
17,19 (d)
7.40
1
2
3
N
4
5
6 7
N
8
NH
9 10
N
11 12
13
S
14
15
16
17 18
19
20
CH321
(2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-phenyl-1,3-thiazole (15)
1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 5.5 Hz, 
1H), 8.35 (t, J = 7.9 Hz, 1H), 8.23 (d, J = 8.3 Hz, 1H), 
7.85 (d, J = 7.6 Hz, 2H), 7.76 (t, J = 6.5 Hz, 1H), 7.44 (s, 
1H), 7.39 (d, J = 7.3 Hz, 1H), 7.30 (t, J = 7.4 Hz, 1H).
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f1 (ppm)
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Solicitacao N. J1125-36
26.01.12   UFPE
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2
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N
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N
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NH
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N
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S
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CH321
(2-(1-(pyridin-2-yl)ethylene)hydrazinyl)-4-phenyl-1,3-thiazole (15)
13C NMR (101 MHz, dmso) δ 168.88, 150.13, 150.01, 147.54, 
144.56, 143.92, 140.96, 134.21, 129.20, 128.36, 126.01, 125.57, 
123.60, 105.85, 13.42.
